問卷

TPIDB > Search Result

Search Result

篩選

List

40Cases

2018-06-15 - 2021-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2022-05-02 - 2028-12-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-05-03 - 2028-01-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-05-19 - 2027-01-25

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2022-12-20

Phase I

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-11-01 - 2022-08-29

Phase III

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-12-01 - 2022-03-22

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-04-01 - 2024-01-10

Phase III

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4